Switching from efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF) or rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks

被引：0

作者：

Orkin, C. ^{[1
]}

DeJesus, E. ^{[2
]}

Ramgopal, M. ^{[3
]}

Crofoot, G. ^{[4
]}

Ruane, P. ^{[5
]}

LaMarca, A. ^{[6
]}

Mills, A. ^{[7
]}

Van der Cam, B. ^{[8
]}

De Wet, J. ^{[9
]}

Rockstroh, J. ^{[10
]}

Lazzarin, A. ^{[11
]}

Rijnders, B. ^{[12
]}

Podzamczer, D. ^{[13
]}

Thalme, A. ^{[14
]}

Stoeckle, M. ^{[15
]}

Chu, H. ^{[16
]}

Porter, D. ^{[16
]}

Liu, H. ^{[16
]}

Cheng, A. ^{[16
]}

Quirk, E. ^{[16
]}

SenGupta, D. ^{[16
]}

Cao, H. ^{[16
]}

机构：

[1] Barts Hlth NHS Trust, London, England

[2] Orlando Immunol Ctr, Orlando, FL USA

[3] Midway Immunol & Res Ctr, Ft Pierce, FL USA

[4] Crofoot Res Ctr, Houston, TX USA

[5] Peter Jerome Ruane, Los Angeles, CA USA

[6] Therafirst Med Ctr, Ft Lauderdale, FL USA

[7] Mills Clin Res, Los Angeles, CA USA

[8] Clin Univ St Luc, Brussels, Belgium

[9] JJ de Wet, Vancouver, BC, Canada

[10] Bonn Univ Hosp, Bonn, Germany

[11] Osped San Raffaele, Milan, Italy

[12] Erasmus MC, Rotterdam, Netherlands

[13] Hosp Univ Bellvitge, Barcelona, Spain

[14] Karolinska Univ Hosp, Stockholm, Sweden

[15] Univ Hosp Basel, Basel, Switzerland

[16] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

来源：

HIV MEDICINE | 2017年 / 18卷

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

P20

引用

页码：21 / 21

页数：1

共 50 条

[31] EFFICACY AND SAFETY OF THE COMBINATION EFAVIRENZ (EFV), TENOFOVIR (TDF) AND EMTRICITABINE (FTC) ONCE A DAY IN TREATMENT OF NAIVE ADULT PATIENTS WITH HIV-1 INFECTION: A SYSTEMATIC REVIEW
Rizzoli-Cordoba, A.
Delgado-Ginebra, I
VALUE IN HEALTH, 2011, 14 (03) : A114 - A114
[32] Associations with HIV-related symptoms and weight change after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate to bictegravir/emtricitabine/tenofovir alafenamide
Lowman, E.
Hardigan, P.
Unger, N.
Lee, N.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 75 - 75
[33] TENOFOVIR DISOPROXIL FUMARATE (TDF) VERSUS EMTRICITABINE PLUS TDF (FTC/TDF) FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN PATIENTS WITH PERSISTENT VIRAL REPLICATION RECEIVING ADEFOVIR DIPIVOXIL
Berg, T.
Moller, B.
Trinh, H.
Chan, S.
Marcellin, P.
Suarcz, E.
Snow-Lampart, A.
Oldach, D.
Sorbel, J.
Borroto-Esoda, K.
Frederick, D.
Rousseau, F.
JOURNAL OF HEPATOLOGY, 2009, 50 : S328 - S328
[34] Metabolic effects of switching to tenofovir alafenamide/emtricitabine/bictegravir (B/F/TAF) from tenofovir difumarate (TDF) or tenofovir alafenamide (TAF) sparing regimens: METABIC study
Busca, C.
Ortega, D.
Martin-Carbonero, L.
Mican, R.
Ramos, L.
Valencia, M.
Montejano, R.
Montes, M.
Diaz-Almiron, M.
Delgado, A.
Bernardino, J.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 150 - 151
[35] Longer term safety of emtricitabine/tenofovir alafenamide (F/TAF) and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP): DISCOVER trial week 96 results
Ogbuagu, O.
Podzamczer, D.
Salazar, L.
Henry, K.
Asmuth, D.
Wohl, D.
Gilson, R.
Shao, Y.
Ebrahimi, R.
Carter, C.
Das, M.
McCallister, S.
Brunetta, J.
Kronborg, G.
Reeves, I.
Spinner, C.
HIV MEDICINE, 2020, 21 : 12 - 12
[36] COST EFFECTIVENESS ANALYSIS OF THE COMBINATION EFAVIRENZ (EFV), TENOFOVIR (TDF) AND EMTRICITABINE (FTC) ONCE A DAY IN TREATMENT OF NAIVE ADULT PATIENTS WITH HIV INFECTION IN MEXICO
Rizzoli-Cordoba, A.
Delgado-Ginebra, I
Pizarro-Castellanos, M.
Castillo, J. J.
VALUE IN HEALTH, 2011, 14 (03) : A119 - A119
[37] RENAL TOXICITY FOR SWITCHING FROM TENOFOVIR/EMTRICITABINE (TDF/FTC) TO ABACAVIR/LAMIVUDINE (ABC/3TC): AN ASSOCIATION TO BE CLARIFIED
Manzini, L.
Borghi, V.
Rusconi, S.
Vergani, B.
Bonfanti, P.
Calza, L.
Narciso, P.
Lenoci, F.
Maggi, P.
Mussini, C.
INFECTION, 2011, 39 : S66 - S67
[38] Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults
Cohen, Calvin
Wohl, David
Arribas, Jose R.
Henry, Keith
Van Lunzen, Jan
Bloch, Mark
Towner, William
Wilkins, Edmund
Ebrahimi, Ramin
Porter, Danielle
White, Kirsten
Walker, Ivan
Chuck, Susan
De-Oertel, Shampa
Fralich, Todd
AIDS, 2014, 28 (07) : 989 - 997
[39] Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?
D'Angelo, Alexa B.
Westmoreland, Drew A.
Carneiro, Pedro B.
Johnson, Jeremiah
Grov, Christian
AIDS PATIENT CARE AND STDS, 2021, 35 (08) : 327 - 334
[40] Satisfaction and knowledge of patients with HIV after switching from tenofovir to tenofovir alafenamide in regimens containing emtricitabine and rilpivirine
Velez-Diaz-Pallares, Manuel
Gramage-Caro, Teresa
Angel Rodriguez-Sagrado, Miguel
Montero-Llorente, Beatriz
Bermejo-Vicedo, Teresa
BIOMEDICA, 2020, 40

← 1 2 3 4 5 →